Primary Cutaneous B-cell Lymphoma: Atlas of Blood Cancer Genomes
PCBCLs represent a heterogeneous group of malignancies with distinct histologic and clinical profiles that include DLBCLLT, PCFCL, and PCMZL. We performed a comprehensive genomic and clinical profiling of PCBCL as part of the Atlas of Blood Cancer Genomes Project. We confirmed DLBCL-LT patients have significantly (p<0.05) worse OS and performed integrative genomic and transcriptomic analyses comparing these subtypes to identify molecular drivers of the stark outcome differences. In DLBCL-LT, mutational profiling revealed significantly higher frequencies of mutations in MYD88 and common aSHM targets including IGLL5, PIM1, and CD79B. In contrast, PCFCL showed significant enrichment of variants among genes involved in NF-kB signaling such as TNFRSF14, TNFAIP3, and NFKB2. Consistent with its aggressive clinical phenotype, DLBCL-LT exhibits frequent copy number alterations across all chromosomes, especially chromosomes 3, 11, and 18 gains, and 6q and 9p losses. We further developed a transcriptomic signature that robustly distinguished PCFCL from PCMZL. The NOTCH pathway was enriched in PCMZL and PI3K/AKT/mTOR signaling in PCFCL, underscoring distinct oncogenic mechanisms. This study reveals profound molecular divergence across PCBCLs, supports the use of RNA-based approaches in aiding the diagnosis of these tumors and identifies subtype-specific features that may inform therapeutic strategies.
- Type: Cancer Genomics
- Archive: European Genome-phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD50000001997 | Illumina NovaSeq X | 50 | |
| EGAD50000001998 | Illumina NovaSeq X | 55 |
